<DOC>
	<DOCNO>NCT01338090</DOCNO>
	<brief_summary>This pilot study evaluation 89Zr-bevacizumab PET image predictive biomarker treatment everolimus patient neuroendocrine tumor . Patients progressive disease last year receive treatment everolimus 10 mg/day orally 89Zr-bevacizumab PET imaging perform start treatment 2 12 week treatment first three patient . If scan 2 week treatment already informative patient undergo scan 12 week . A scan consider already informative scan show least 30 % decrease uptake case response , least 30 % increase uptake case disease progression . Four day scan patient inject intravenously 37 MBq , protein dose 5 mg 89Zr-bevacizumab . At day 1 , day 15 day 99 , PET image make visualization quantification VEGF tumor lesion blood draw determination angiogenesis mTOR pathway related biomarkers .</brief_summary>
	<brief_title>89Zr-bevacizumab PET Imaging Patients With Neuroendocrine Tumors</brief_title>
	<detailed_description>1 . Rationale : Profound angiogenesis important characteristic neuroendocrine tumor . Antiangiogenic drug include sunitinib , bevacizumab everolimus show antitumor activity neuroendocrine tumor . The investigator participate RAD001 study neuroendocrine tumor . From preclinical study include study perform lab investigator know everolimus downregulates VEGF . Currently possible predict individual patient benefit treatment mTOR inhibitor . A predictive biomarker efficacy mTOR inhibitor urgently need would helpful , predictive biomarker may facilitate development combination therapy , individual titration dose , may facilitate early clinical study . Furthermore , may spare patient unnecessary side effect . mTOR inhibitor may fail individual patient angiogenesis sufficiently inhibit . Non-invasive image VEGF early start treatment may predictive value treatment efficacy . Within UMCG investigator active ongoing research line molecular imaging . The investigator develop part 89Zr-bevacizumab PET label non-invasive measurement VEGF level tumor surround microenvironment . This tracer give insight tumor ' dependency angiogenesis investigator already proven VEGF-receptor tyrosine kinase inhibitor . Currently tracer use clinical trial . The investigator would like examine whether neuroendocrine tumor produce VEGF whether differ response inhibition VEGF mTOR . 2 . Objectives : The primary objective evaluate feasibility 89Zr-bevacizumab-PET image predictive biomarker treatment everolimus patient neuroendocrine tumor . The secondary Objectives follow : - To explore 89Zr-bevacizumab PET image differentiate patient progressive neuroendocrine tumor patient non-progressive disease early treatment everolimus . - To explore relationship VEGF pathway relate blood biomarkers change 89Zr-bevacizumab tumor uptake .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>adult patient metastatic neuroendocrine tumor radiological documentation progressive disease past year measurable disease accord RECIST criterion Adequate bone marrow function show : ANC ≥ 1.5 x 109/L , Platelets ≥ 100 x 109/L , Hb &gt; 9 g/dL . Adequate liver function : serum bilirubin : ≤ 1.5 x ULN , ALT AST ≤ 2.5x ULN . Patients know liver metastasis : AST ALT ≤ 5x ULN . Adequate renal function : serum creatinine ≤ 1.5 x ULN . Fasting serum cholesterol ≤300 mg/dL OR 7.75 mmol/L AND fast triglyceride ≤ 2.5 x ULN . NOTE : In case one threshold exceed , patient include initiation appropriate lipid lower medication uncontrolled medical condition ( eg , unstable angina , symptomatic heart failure , serious intercurrent infection ) psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule study Patients uncontrolled diabetes mellitus define fast blood sugar &gt; 1.5 x ULN . Prior therapy RAD001 ( everolimus ) rapamycins ( sirolimus , temsirolimus ) . Concomitant medication know inhibit , induce substrate isoenzyme CYP3A exclude unless drug medically necessary substitute available . If acceptable substitute , special precaution take patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>VEGF imaging</keyword>
	<keyword>neuroendocrine tumor</keyword>
	<keyword>biomarker</keyword>
	<keyword>mTOR inhibition</keyword>
</DOC>